Global Nexus Director Matthew Miller has been named University Scholar — an honour recognizing international research excellence, mentorship, and community impact. Congratulations to Dr. Miller and the other outstanding recipients! 👏 brighterworld.mcmaster.ca/articles/uni...

🦠 Clinical Trial Update 🦠 McMaster University's inhaled COVID-19 #vaccine safely generates immune responses associated with protection in the lungs, according to phase-1 clinical trial data published in Nature Communications. Our inhaled vaccine is now in ongoing phase-2 trials. Learn more 👇

Today, on the five-year anniversary of the WHO's pandemic declaration, we're proud to commence Phase-II human trials on our inhaled aerosol vaccine. Learn more about this exciting next-gen vaccine candidate, including how to enrol in the ongoing study. 👇 healthsci.mcmaster.ca/made-at-mcma...

New from @macleans.bsky.social: How IIDR member Jon Stokes is working at the intersect of academia and industry to get new antibiotics to the finish line faster. #IDSky macleans.ca/society/heal...

The Government of Canada announced today a $4M investment in Global Nexus, which will be leveraged for bold new drug discovery and development initiatives at McMaster. brighterworld.mcmaster.ca/articles/fed...

Hey #IDSky, #Microsky and #ImmunoSky - I'm so pleased that @mcmasteriidr.bsky.social and @mcmasternexus.bsky.social are now here, as well as microbiologists extraordinaire @gdwantibiotics.bsky.social @dr-lori-burrows.bsky.social and @lkalan.bsky.social - get these folks in some #starterpacks!

Putting the 'ant' in antibiotic discovery: how IIDR researchers are harnessing an eons-old relationship between ants, fungi, and bacteria to find new antimicrobial medicines. #AMR #WorldAMRAwarenessWeek www.youtube.com/watch?v=jpt9...